These results offer new insights into the molecular mechanisms underlying MC functional heterogeneity in ccRCC and emphasize the potential of the IL1B/ADRB2 axis as a therapeutic target for cancer. This evidence concerns the gene ADRB2 and nonpapillary renal cell carcinoma.